Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

Table 3

Pharmacokinetic parameters and statistical analysis of etravirine after administration of etravirine 200 mg bid for two weeks in combination with atazanavir/ritonavir 300/100 mg qd or 400/100 mg qd and one NRTI and from the pooled DUET pharmacokinetic substudies at Week 4 [21].

Pharmacokinetics of ETR mean ± SD; : median (range)	Pooled DUET [21]: ETR 200 mg bid + DRV/r 600/100 mg bid, Week 4; (reference); ()	ATV/r 300/100 mg qd; + one NRTI + ETR 200 mg bid, Week 2 (Test 1); (^*)	ATV/r 400/100 mg qd; + one NRTI + ETR 200 mg bid, Week 2 (Test 2); (^†)
, ng/mL	545.0 ± 818.6	422.2 ± 327.9	316.6 ± 215.4
, ng/mL	452.6 ± 806.0	425.1 ± 328.1	286.5 ± 198.0
, ng/mL	879.6 ± 1030	773.0 ± 360.5	628.7 ± 294.0
, h	3.95 (0.08–6.08)	4.00 (3.00–9.00)	4.00 (2.00–6.07)
, ng⋅h/mL	7964 ± 11180	7629 ± 4213	5171 ± 2695
LSM ratio (90% CI) of test versus reference^‡
		Test 1 versus reference	Test 2 versus reference
	—	1.07 (0.60–1.90)	0.83 (0.54–1.29)
	—	1.06 (0.78–1.46)	0.87 (0.65–1.18)
	—	1.24 (0.88–1.76)	0.84 (0.60–1.18)

ATV/r: atazanavir/ritonavir; : area under the plasma concentration-time curve from time 0 to 12 hours; bid: twice daily; CI: confidence interval; : maximum plasma concentration; : minimum plasma concentration; : predose plasma concentration; ETR: etravirine; LSM: least square mean; NRTI: nucleoside reverse transcriptase inhibitor; qd: once daily; SD: standard deviation; : time to maximum plasma concentration.
^* for , for , for , ^† for , and for and ; ^‡calculated based on log-transformed pharmacokinetic parameters.